Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10509447 | Drug and Alcohol Dependence | 2013 | 6 Pages |
Abstract
LY379268 selectively reduced the motivation to self-administer METH. In contrast to data with other compounds, the sensitivity to the effects of LY379268 did not change following extended access to METH self-administration. Group II mGluR agonists, therefore, may represent a relatively new class of compounds for the development of pharmacotherapies for METH addiction.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Jordan T. Crawford, David C.S. Roberts, Thomas J.R. Beveridge,